Skip to main content
Transgene logo

Transgene — Investor Relations & Filings

Ticker · TNG ISIN · FR0005175080 LEI · 969500PDJW8N0FSGGK69 PA Professional, scientific and technical activities
Open in API
Filings indexed 796 across all filing types
Latest filing 2026-05-04 AGM Information
Country FR France
Listing PA TNG

About Transgene

https://www.transgene.fr/en/

Transgene is a clinical-stage biotechnology company that designs and develops immunotherapies for the treatment of cancer. The company's strategy is based on two proprietary technology platforms. The myvac® platform is used to create individualized neoantigen therapeutic vaccines, such as its clinical candidate TG4050, which leverages advanced genetic engineering and artificial intelligence. The invir.IO® platform is dedicated to developing innovative, multifunctional oncolytic viruses engineered to directly destroy cancer cells and modulate the tumor microenvironment, thereby enhancing the patient's immune response against the tumor.

Recent filings

Filing Released Lang Actions
Mise à disposition des documents préparatoires à l'Assemblée générale du 22 mai 2026
AGM Information
2026-05-04 French
Availability of Preparatory Documents for the Combined General Meeting of May 22, 2026
AGM Information
2026-05-04 English
Transgene fait le point sur ses activités et sa situation financière au premier trimestre 2026
Earnings Release Classification · 1% confidence The document is a press release (“COMMUNIQUÉ DE PRESSE”) providing Transgene’s first-quarter 2026 operational and financial highlights (revenues, cash position, cash consumption) along with R&D updates. It is not a full interim/quarterly report (IR) with complete financial statements but an initial announcement of quarterly results. Therefore, it falls under the “Earnings Release” category (ER). Q1 2026
2026-04-29 French
Transgene Provides Business and Financial Update for Q1 2026
Earnings Release Classification · 1% confidence The document is a corporate press release providing a business and financial update for Q1 2026, including topline revenue, cash position, burn rate, and clinical trial progress. It is not the full quarterly report (no comprehensive financial statements) but is an initial announcement of period financial results and operational highlights, matching the Earnings Release definition. Q1 2026
2026-04-29 English
Transgene annonce la fin de la randomisation des patients de la partie Phase 2 de l’essai clinique évaluant TG4050 dans le traitement adjuvant des cancers de la tête et du cou
Regulatory Filings Classification · 0% confidence The document is a corporate press release (‘COMMUNIQUÉ DE PRESSE’) providing a clinical trial milestone update (end of randomization in Phase 2), with no financial results, capital changes, or statutory report attachments. It is not an earnings release, dividend notice, financing update, regulatory prospectus, or governance filing. It does not announce the publication of a formal report but is a general corporate announcement, thus falling under the fallback category of general regulatory/regulatory announcement (RNS).
2026-04-13 French
Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
Regulatory Filings Classification · 1% confidence The text is a corporate press release announcing clinical trial progress (completion of patient randomization in Phase 2) with forward‐looking statements and no financial results, governance changes, capital transactions, voting outcomes, or detailed report content. It does not constitute an earnings release, annual/interim report, investor presentation or any other specified category, so it falls into the general “Regulatory Filings” fallback category (RNS).
2026-04-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.